Research programme: antibody therapeutics - Adimab/Kite Pharma

Drug Profile

Research programme: antibody therapeutics - Adimab/Kite Pharma

Alternative Names: CAR-T therapeutics - Adimab/Kite

Latest Information Update: 23 Jun 2015

Price : $50

At a glance

  • Originator Adimab; Kite Pharma
  • Class Antibodies
  • Mechanism of Action Immunostimulants; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 16 Jun 2015 Early research in Undefined indication in USA (unspecified route)
  • 16 Jun 2015 Adimab and Kite Pharma agree to co-develop chimeric antigen receptor T cell therapeutics in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top